Relationship between ces2 genetic variations and rifampicin metabolism

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1281-1284

  Song, Sang Hoon ^a,b   Chang, Ho Eun ^c   Jun, Sun Hee ^c   Park, Kyoung Un ^a,c   Lee, Jae Ho ^a,c   Lee, Eun Mi ^d   Song, Young Han ^d   Song, Junghan ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Hallym University   (South Korea)

Author keywords

Carboxylesterase 2; Pharmacogenetics; Promoters; Tuberculosis

Indexed keywords

CARBOXYLESTERASE; CARBOXYLESTERASE 2; LUCIFERASE; RIFAMPICIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; EXON; GENE FREQUENCY; GENE SEQUENCE; GENETIC RISK; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; INTRON; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS;

CARBOXYLESTERASE 2; PHARMACOGENETICS; PROMOTERS; TUBERCULOSIS;

3' UNTRANSLATED REGIONS; ALLELES; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBOXYLESTERASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEALKYLATION; GENE FREQUENCY; GENETIC VARIATION; HUMANS; LUCIFERASES; MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RIFAMPIN;

EID: 84884967291     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt036     Document Type: Article

References (17)

1. Kimerling ME, Phillips P, Patterson P et al. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998; 113: 1178-83.
2. Mehta JB, Shantaveerapa H, Byrd RP et al. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001; 120: 1520-4.
3. Ferraldeschi R,NewmanWG. Pharmacogeneticsand pharmacogenomics: a clinical reality. Ann Clin Biochem 2011; 48: 410-7.
4. Donald PR, Sirgel FA, Venter A et al. The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis 2004; 39: 1425-30.
5. Weiner M, Peloquin C, Burman Wet al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother 2010; 54: 4192-200.
6. Jamis-Dow CA, Katki AG, Collins JM et al. Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica 1997; 27: 1015-24.
7. Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 2006; 95: 1177-95.
8. Saito S, Iida A, Sekine A et al. Catalog of 680 variations among eight cytochrome P450 (CYP) genes, nine esterase genes, and two other genes in the Japanese population. J Hum Genet 2003; 48: 249-70.
9. Kim SR, Nakamura T, Saito Y et al. Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2). Drug Metab Pharmacokinet 2003; 18: 327-32.
10. Ribelles N, López-Siles J, Sánchez A et al. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Curr Drug Metab 2008; 9: 336-43.
11. Bellott R, Le Morvan V, Charasson V et al. Functional study of the 830C.G polymorphism of the human carboxylesterase 2 gene. Cancer Chemother Pharmacol 2008; 61: 481-8.
12. Fujiyama N, Miura M, Satoh S et al. Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Xenobiotica 2009; 39: 407-14.
13. Yamada S, Richardson K, Tang M et al. Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. Pharmacogenomics J 2010; 10: 524-36.
14. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-83.
15. Song SH, Jun SH, Park KU et al. Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007; 21: 1331-8.
16. Park H, Bang Y, Park K et al. Molecular and biochemical characterization of the GALK1 gene in Korean patients with galactokinase deficiency. Mol Genet Metab 2007; 91: 234-8.
17. Kubo T, Kim SR, Sai K et al. Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). Drug Metab Dispos 2005; 33: 1482-7.